Please ensure Javascript is enabled for purposes of website accessibility

Why I Own Novocure Stock (NVCR)

By Connor Allen and Brian Orelli, PhD – Aug 22, 2022 at 10:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Motley Fool contributor Brian Orelli shares why he loves this stock

Brian Orelli, biotech contributor and writer at The Motley Fool, joins the channel to discuss why he owns Novocure (NVCR -1.84%) stock. Check out his reasoning in this video!

*Stock prices used were the midday prices of Aug. 10, 2022. The video was published on Aug. 21, 2022.

Connor Allen has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Novocure. The Motley Fool has a disclosure policy.

Stocks Mentioned

NovoCure Stock Quote
$80.04 (-1.84%) $-1.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.